A Randomized, Double-Blind, Placebo-Controlled Trial of Levetiracetam for Dyskinesia in Parkinson's Disease

作者：Wong Kitty K; Alty Jane E; Goy Amanda G; Raghav Sanjay; Reutens David C; Kempster Peter A^*

来源：Movement Disorders, 2011, 26(8): 1552-1555.

DOI：10.1002/mds.23687

• Parkinson's disease
• levodopa
• dyskinesia
• levetiracetam

Background: This randomized double blind, placebo-controlled crossover study investigated the antidyskinetic effects of levetiracetam in Parkinson's disease.
Methods: Sixteen participants with levodopa-induced dyskinesia were enrolled. Hourly videotaped dyskinesia assessments scored by the Goetz method and hourly Unified Parkinson's Disease Rating Scale motor sub-scale scoring were conducted on 1 day at the end of each treatment period.
Results: Dyskinesia was slightly less on placebo (P = .26). Patient diary records also showed less dyskinesia on placebo (P = .10). Parkinsonism was a little worse on levetiracetam, at borderline statistical significance (P = .05).
Conclusions: Levetiracetam was well tolerated at doses up to 2000 mg per day, but we did not detect any antidyskinetic properties.

• 出版日期2011-7